会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO
    • 重组人EPO-FC融合蛋白,具有延长的半衰期和增强的生殖活性
    • WO2007085084A1
    • 2007-08-02
    • PCT/CA2007/000107
    • 2007-01-25
    • NOVAGEN HOLDING CORPORATIONWANG, HaitaoDU, YongZHANG, RuiXU, JingLIU, Longbin
    • WANG, HaitaoDU, YongZHANG, RuiXU, JingLIU, Longbin
    • C12N15/62A61K38/18A61K47/42A61K47/48A61P7/00C07K14/505C07K16/18C07K19/00C12N15/13C12N15/18C12P21/02
    • C07K14/505A61K9/0019A61K38/00A61K47/6811C07K2317/53C07K2319/30
    • A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.
    • 描述了包含与免疫球蛋白肽部分连接的人促红细胞生成素肽部分的重组融合蛋白。 与天然存在的或重组的天然人促红细胞生成素相比,融合蛋白在体内具有延长的半衰期。 在本发明的一个实施方案中,蛋白质的体内半衰期比天然人促红细胞生成素高至少三倍。 与天然人促红细胞生成素相比,融合蛋白也表现出增强的红细胞生物活性。 在一个实施方案中,融合蛋白包含人促红细胞生成素(EPO)分子的完整肽序列和人免疫球蛋白IgG1的Fc片段的肽序列。 融合蛋白中的Fc片段包括人免疫球蛋白IgG1的铰链区,CH2和CH3结构域。 EPO分子可以直接连接到Fc片段,以避免外来的肽接头并且当在体内施用时减轻免疫原性应答的风险。 在一个实施方案中,铰链区是在氨基酸6具有非半胱氨酸残基的人Fc片段变体。本发明还涉及编码融合蛋白和转染细胞系的核酸和氨基酸序列以及用于产生融合蛋白的方法。 本发明还包括包含融合蛋白的药物组合物和使用融合蛋白和/或药物组合物的方法,例如刺激需要治疗的受试者的红细胞生成。
    • 4. 发明申请
    • POWER CONTROL METHOD AND APPARATUS FOR WIRELESS COMMUNICATION SYSTEM
    • 用于无线通信系统的功率控制方法和设备
    • WO2008073737A2
    • 2008-06-19
    • PCT/US2007/086245
    • 2007-12-03
    • ADAPTIX, INC.WANG, Haitao
    • WANG, Haitao
    • H04Q7/20
    • H04W52/10H04W52/08
    • Open loop transmit power calculations made by a wireless communication receiving device use only the portion of the received signal power that is due to the transmitting device serving the wireless device, rather than using the total received power from all transmitting devices. In one embodiment a discernable signal trait of, such as a preamble, is used to identify signal power from a serving transmitter. In some embodiments, open loop power control may also used to transmit power limits established from closed loop power control sessions, in order to minimize power fluctuations. Digitally scaling data values compensates for transmitter power level settings by adjusting data values prior to modulation such that the modulated waveform contains a different power level than the original data values would provide.
    • 由无线通信接收设备进行的开环发射功率计算仅使用由于服务于无线设备的发射设备而导致的接收信号功率的部分,而不是使用来自所有设备的总接收功率 传输设备。 在一个实施例中,诸如前导码的可辨别信号特征用于识别来自服务发射机的信号功率。 在一些实施例中,开环功率控制还可以用于传输从闭环功率控制会话建立的功率限制,以最小化功率波动。 数字调节数据值通过在调制之前调节数据值来补偿发射机功率电平设置,使得调制波形包含与原始数据值相比不同的功率电平。